Prognostic utility of cell-free hydroxymethylation in small cell lung cancer

无细胞羟甲基化在小细胞肺癌中的预后效用

• 批准号: 486017
• 负责人: Li Janice
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486017&lang=en
• 关键词: 5-Hmc-Seal; Cell-Free Dna; Crispr; Disease Relapse; Epigenetic Biomarker; Hydroxymethylcytosine; Liquid Biopsy; Prognosis; Small Cell Lung Cancer

Small-cell lung cancer (SCLC) is an aggressive disease that develops and spreads rapidly. Although most SCLC patients respond well to chemotherapy initially, many of their tumours grow back, therefore only 1-5% of SCLC patients will survive past 5 years.

小细胞肺癌（SCLC）是一种侵袭性疾病，发展和扩散迅速。虽然大多数SCLC患者最初对化疗反应良好，但许多肿瘤会复发，因此只有1-5%的SCLC患者能存活5年。